|
注册号: Registration number: |
ChiCTR-IIR-17010453 |
|
最近更新日期: Date of Last Refreshed on: |
2017-01-17 00:08:40 |
|
注册时间: Date of Registration: |
2017-01-16 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
SCIT干预对重性抑郁症患者脑功能影响的临床研究 |
|
Public title: |
The correlation of SCIT intervention and brain network connection in patient with major depressive disorder |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
SCIT干预对重性抑郁症患者脑功能影响的临床研究 |
|
Scientific title: |
The correlation of SCIT intervention and brain network connection in patient with major depressive disorder |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
张勇 |
研究负责人: |
张勇 |
|
Applicant: |
Yong Zhang |
Study leader: |
Yong Zhang |
|
申请注册联系人电话: Applicant telephone: |
+86 13662166238 |
研究负责人电话:
Study leader's |
+86 022-88188256 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
zhyzhangyong003@163.com |
研究负责人电子邮件: Study leader's E-mail: |
zhyzhangyong003@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
天津市河西区柳林路13号 |
研究负责人通讯地址: |
天津市河西区柳林路13号 |
|
Applicant address: |
13 Liulin Road, Hexi District, Tianjin, China |
Study leader's address: |
13 Liulin Road, Hexi District, Tianjin, China |
|
申请注册联系人邮政编码: Applicant postcode: |
300222 |
研究负责人邮政编码: Study leader's postcode: |
300222 |
|
申请人所在单位: |
天津市安定医院(天津市精神卫生中心) |
||
|
Applicant's institution: |
Tianjin Anding Hospital (Tianjin Mental Health Centre) |
||
|
研究负责人所在单位: |
天津市安定医院(天津市精神卫生中心) |
||
|
Affiliation of the Leader: |
Tianjin Anding Hospital (Tianjin Mental Health Centre) |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2016-07 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
天津市安定医院(天津市精神卫生中心)医学伦理委员会 |
||
|
Name of the ethic committee: |
Ethic Committee of Tianjin Anding Hospital (Tianjin Mental Health Centre) |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
1990-01-01 00:00:00 | ||
|
伦理委员会联系人: |
|
||
|
Contact Name of the ethic committee: |
|
||
|
伦理委员会联系地址: |
|
||
|
Contact Address of the ethic committee: |
|
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
||
|
研究实施负责(组长)单位: |
天津市安定医院(天津市精神卫生中心) |
||||||||||||||||||||||
|
Primary sponsor: |
Tianjin Anding Hospital (Tianjin Mental Health Centre) |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
天津市河西区柳林路13号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
13 Liulin Road, Hexi District, Tianjin, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
天津市卫生行业重点攻关项目 |
||||||||||||||||||||||
|
Source(s) of funding: |
The Key Research Project of Tianjin Health Bureau |
||||||||||||||||||||||
|
研究疾病: |
抑郁症 |
||||||||||||||||||||||
|
Target disease: |
major depressive disorder |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
I期临床试验 | ||||||||||||||||||||||
|
Study phase: |
1 |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
本研究采用病例对照和干预研究方法,利用rs-fMRI技术以及相关因子检测,通过病例对照、以及对服药MDD患者分别给予8周SCIT和CBT治疗,比较并分析各组间脑区功能特征、外周神经营养因子水平、临床症状和总体功能等治疗结局的差异性和关联性,分析SCIT治疗模式的脑功能和神经营养因子机制,为SCIT干预模式广泛应用临床提供科学依据。 |
||||||||||||||||||||||
|
Objectives of Study: |
By using the case-control study, we compare the differences of the brain network connection and peripheral neurotrophic factors between the MDD and health control group, By randomized paralle control study, we investigate the differences of fMRI and related biomarkers between the SCIT group and CBT group during the 8-week intervention, Further we analyze the correlation of SCIT intervention and changing of fMRI and related biomarkers in MDD patients, to explore the possible biological mechanism of SCIT intervention in major depressive disorder. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
|||||||||||||||||||||||
|
Inclusion criteria |
|||||||||||||||||||||||
|
排除标准: |
受试者符合下列任意一条都将被排除: (1)有严重躯体或脑器质性疾病史以及颅脑外伤史; (2)严重精神发育迟滞者; (3)经磁共振检查发现脑结构异常; (4)在实验过程中不合作或不能有效完成本实验者; (5)有药物,酒精或其他精神活性物质滥用者,或者重性精神疾病 (6)目前伴有严重自杀观念或行为,或伴有精神病性症状 (7)目前接受其他心理治疗者。 |
||||||||||||||||||||||
|
Exclusion criteria: |
Patients were excluded if they fell into any of the following categories: 1. had a history of serious physical, cerebral organic history or head injury; 2. mental retardation; 3. brain structural abnormalities; 4. uncooperative or can not effectively accomplish this experimenter; 5. drugs, alcohol or other psychotropic active substance abusers;or other severe psychiatric diseases. 6. with severe suicidal attempt or behavior, or with severe psychotic symptoms. 7. being received other psychological therapy. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2016-12-31 00:00:00至 To 2019-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2017-01-01 00:00:00 至 To 2018-06-30 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
正在进行 Recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
随机数字表 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
random number table |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
|
|
Blinding: |
|
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
试验完成后6个月内公开 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
Within six months after the trial complete |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
spss |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
spss |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |